CDKN2A and cancer: Genomic analysis has been used to uncover intratumor heterogeneity in terms of copy number alterations in EGFR and CDKN2A/B/p14ARF as early events, and aberrations in PDGFRA and PTEN as later events during progression of cancer (116).